T Arber1, A Ruffion2, J-E Terrier3, P Paparel4, N Morel Journel5, D Champetier6, I Dominique7. 1. Service d'urologie du Pr. Ruffion, centre hospitalier Lyon sud, 165, chemin du grand Revoyet, 69310 Pierre-Benite, France. Electronic address: theo.arber@chu-lyon.fr. 2. Service d'urologie du Pr. Ruffion, centre hospitalier Lyon sud, 165, chemin du grand Revoyet, 69310 Pierre-Benite, France. Electronic address: alain.ruffion@chu-lyon.fr. 3. Service d'urologie du Pr. Ruffion, centre hospitalier Lyon sud, 165, chemin du grand Revoyet, 69310 Pierre-Benite, France. Electronic address: jean-etienne.terrier01@chu-lyon.fr. 4. Service d'urologie du Pr. Ruffion, centre hospitalier Lyon sud, 165, chemin du grand Revoyet, 69310 Pierre-Benite, France. Electronic address: philippe.paparel@chu-lyon.fr. 5. Service d'urologie du Pr. Ruffion, centre hospitalier Lyon sud, 165, chemin du grand Revoyet, 69310 Pierre-Benite, France. Electronic address: nicolas.morel-journel@chu-lyon.fr. 6. Service d'urologie du Pr. Ruffion, centre hospitalier Lyon sud, 165, chemin du grand Revoyet, 69310 Pierre-Benite, France. Electronic address: denis.champetier@chu-lyon.fr. 7. Service d'urologie du Pr. Ruffion, centre hospitalier Lyon sud, 165, chemin du grand Revoyet, 69310 Pierre-Benite, France. Electronic address: ines.dominique@chu-lyon.fr.
Abstract
AIMS: The objective of this study was to assess the effectiveness and the complications rate following continent cutaneous channels (CCC) procedures, at short and medium term follow-up (FU). MATERIALS & METHODS: A continuous retrospective case series (2008-2018): all patients who have undergone a CCC for neurogenic bladder were included in our department. The primary outcome was the effectiveness of CCC defined by the status of catheterizability (by the patient or a care-giver), continence of the tube, and absence of reintervention at 3 and 12 months FU. The secondary outcome was the prevalence of postoperative complications at 3 and 12 months FU. RESULTS: Fifty-three patients were included during the study period in our department. Median follow up was 3,3 years (1.5-6.1). The overall effectiveness of CCC was 67.9% (n=36/53) at 3 months FU and 45,3% (n=24) at 12 months FU. The global rate of complications was 60.4% (n=32/53) at 3 months, and 73.6% (n=39/73) at 12 months FU. The statistical analysis showed no statistical differences on efficacy and complications in the different subgroups of CCC. CONCLUSIONS: In the current series, the effectiveness and the complications rates following CCC were comparable across the procedure types. LEVEL OF EVIDENCE: 4.
AIMS: The objective of this study was to assess the effectiveness and the complications rate following continent cutaneous channels (CCC) procedures, at short and medium term follow-up (FU). MATERIALS & METHODS: A continuous retrospective case series (2008-2018): all patients who have undergone a CCC for neurogenic bladder were included in our department. The primary outcome was the effectiveness of CCC defined by the status of catheterizability (by the patient or a care-giver), continence of the tube, and absence of reintervention at 3 and 12 months FU. The secondary outcome was the prevalence of postoperative complications at 3 and 12 months FU. RESULTS: Fifty-three patients were included during the study period in our department. Median follow up was 3,3 years (1.5-6.1). The overall effectiveness of CCC was 67.9% (n=36/53) at 3 months FU and 45,3% (n=24) at 12 months FU. The global rate of complications was 60.4% (n=32/53) at 3 months, and 73.6% (n=39/73) at 12 months FU. The statistical analysis showed no statistical differences on efficacy and complications in the different subgroups of CCC. CONCLUSIONS: In the current series, the effectiveness and the complications rates following CCC were comparable across the procedure types. LEVEL OF EVIDENCE: 4.
Authors: Courtney T Shepard; Amanda M Pocratsky; Brandon L Brown; Morgan A Van Rijswijck; Rachel M Zalla; Darlene A Burke; Johnny R Morehouse; Amberley S Riegler; Scott R Whittemore; David Sk Magnuson Journal: Elife Date: 2021-12-02 Impact factor: 8.140